 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced that it has achieved a key milestone with U.S. Food and Drug Administration FDA clearance of an Investigational New Drug IND application for AXA1125, enabling the company to proceed directly into a Phase 2b clinical trial. AXA1125 is Axcellas multi-tar 